More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$14374994
EPS
-5.02
P/E ratio
--
Price to sales
12.19
Dividend yield
--
Beta
0.439882
Previous close
$1.41
Today's open
$1.39
Day's range
$1.33 - $1.50
52 week range
$1.30 - $29.98
show more
CEO
Richard N. Kender
Employees
66
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
10195031
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027 Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response of diarrhea following treatment with SER-155 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2026 financial results and announced it is progressing plans for a next study evaluating SER-155 for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC) in patients initiating immune checkpoint inhibitor (ICI) cancer therapy, which is expected to include a dose optimization component.
GlobeNewsWire • Nov 4, 2026

Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates
Seres Therapeutics (MCRB) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to earnings of $0.94 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b clinical study of SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT) have been published in the November 3, 2026 issue of Nature Medicine.
GlobeNewsWire • Nov 3, 2026

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube
GlobeNewsWire • Oct 15, 2026

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”). The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by Seres' board of directors in December 2022. The stock options have an exercise price of $5.72 per share. Each option will vest as to 25% of the total number of shares subject to the option on the first anniversary of the individual's date of hire and as to 6.25% of the total number of shares subject to the option upon completion of each three full months of service to the Company thereafter.
GlobeNewsWire • Sep 8, 2026

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual Global Investment Conference taking place in New York, NY and will present a company overview at 2 p.m. ET on September 15, 2026.
GlobeNewsWire • Sep 1, 2026

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) IST data support SER-155 as a potential treatment for irEC that may allow patients to continue cancer therapy; Company evaluating irEC clinical development strategy in consultation with KOLs Seres engaging potential partners, seeking capital to advance its SER-155 programs, including for the prevention of bloodstream infections in patients undergoing allo-HCT and those experiencing irEC Seres announces agreement to exit additional leased space early, further reducing ongoing facility-related cash costs, which follows announcement of balance sheet strengthening and facilities cost reduction transactions in June 2026 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported second quarter 2026 financial results and provided business updates.
GlobeNewsWire • Aug 5, 2026

Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluation of the live biotherapeutic as a potential non-immunosuppressive treatment option for cancer patients experiencing the gastrointestinal toxicity.
MarketBeat • Jul 10, 2026

Seres Therapeutics Posts Early Data for Cancer Therapy Complication
Seres Therapeutics Inc. (NASDAQ:MCRB) on Wednesday reported topline results from an investigator-sponsored trial evaluating SER-155 in patients with immune-related enterocolitis (irEC), with most participants achieving a steroid-free clinical response after treatment.
Benzinga • Jul 8, 2026

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seeking Alpha • Jul 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Seres Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.